The following slide deck was published by ProPhase Labs, Inc.
GARDEN CITY, NY, Sept. 06, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be featured as a presenting company at the H.C. Wainwright 24 th Annual Global Investment Conference on September 12, 2022 at 2:30 pm, Eastern Time. The conference is being held as a hybrid in-person/virtual event from September 12 to 14, 2022.
ProPhase Labs, Inc (NASDAQ:NASDAQ:PRPH) Q2 2022 Earnings Conference Call August 11, 2022, 09:00 AM ET Company Participants Ted Karkus - Chairman & Chief Executive Officer Conference…
ProPhase Labs press release (NASDAQ:PRPH): Q2 GAAP EPS of $0.40 beats by $0.24.Revenue of $29.09M (+218.3% Y/Y) beats by $5.77M.Shares +4.96% PM.
Record Q2 2022 Net Revenues of $29.1 Million; Up 218% Year-over-Year
Companies Reporting Before The Bell • Magic Software (NASDAQ: MGIC ) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. • Dingdong (Cayman) (NYSE: DDL ) is likely to report earnings for its second quarter. • Evelo Biosciences (NASDAQ: EVLO ) is projected to report earnings for its second quarter. • Affimed (NASDAQ: AFMD ) is estimated to report quarterly loss at $0.17 per share on revenue of $8.67 million. • CorEnergy Infr Trust (NYSE: CORR ) is expected to report earnings for its second quarter. • Six Flags Entertainment (NYSE: SIX ) is expected to report earnings for its second quarter. • Where Food Comes From (NASDAQ: WFCF ) is projected to report earnings for its second quarter. • BurgerFi International (NASDAQ: BFI ) is estimated to report earnings for its second quarter. • Smith-Midland (NASDAQ: SMID ) is expected to report earnings for its second quarter. • Kala Pharmaceuticals (NASDAQ: KALA ) is expected to report earnings for its second quarter.
ProPhase Labs (PRPH) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open.The consensus EPS Estimate is $0.16 and the consensus Revenue Estimate…
GARDEN CITY, NY, Aug. 04, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on Thursday, August 11, 2022 at 11:00 a.m. Eastern time to discuss its results for the second quarter ended June 30,2022. A press release detailing these results will be issued prior to the call.
ProPhase Labs (PRPH) stated Tuesday that it has received Board''s approval to repurchase up to $6M of its common shares. The buyback plan is to be effective three business days after…
ProPhase Labs has expanded its in-house testing capabilities for the diagnostics of the new clinical chemistry, immunoassay, hematology, hemostasis, and urinalysis analyzers.
DSS (DSS) shares popped around 17% after the company announced on Thursday the licensing of Impact BioMedical''s Linebacker portfolio to ProPhase Labs (PRPH).Global BioLife, a subsidiary…
ProPhase Labs (PRPH) on Thursday said its unit had entered into a licensing agreement with Global BioLife for two inhibitors that can be used to treat multiple indications, with an…
Garden City, NY, July 19, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that it will host a live webcast on Thursday, July 21, 2022, at 11:30 a.m. EST / 8:30 a.m. PST. ProPhase Labs’ CEO and Chairman of the Board of Directors, Ted Karkus, will host the webcast and review the latest developments at ProPhase Labs and
100% technical buy signals. 12 new highs and up 53.07% in the last month. 1,650 investors are monitoring the stock on Seeking Alpha.
Diagnostics and genomics company ProPhase Labs (PRPH) announced the formation of a unit called ProPhase BioPharma ((PBIO)) for the licensing and development of drugs, compounds…
The trading price of ProPhase Labs Inc. (NASDAQ:PRPH) closed lower on Friday, June 17, closing at $10.39, -1.70% lower than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $10.07 … ProPhase Labs Inc. (NASDAQ: PRPH) Can Raise Stock -1.70% More Read More »
Analysts expect that ProPhase Labs, Inc. will post $18.05 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided…
May 23-26, 2022 (HYBRID CONFERENCE)
ProPhase Labs had a stellar quarter both in terms of revenues and net income. It also declared another special dividend. Click here to read why I believe PRPH is a buying opportunity now.
GARDEN CITY, NY, July 01, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH) (ProPhase or the Company), a diversified medical science and technology company, announced today that it has retained CORE IR, a leading investor relations, public relations and strategic advisory firm, to assist the Company with investor relations, public relations and shareholder communications services.
GARDEN CITY, NY, June 28, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH) (ProPhase or the Company), a diversified medical science and technology company, today announces that it has been added to the Russell Microcap Index. This milestone became effective at the conclusion of the 2021 Russell Indexes annual reconstitution, which occurred immediately following the U.S. market opening today, June 28, 2021.
ProPhase Precision Medicine, Inc. and ProPhase Global Healthcare , Inc. to Expand Opportunities in Genomics and International Testing Services
CEO Ted Karkus to Present at Conference on Thursday , June 10 th , 2021
First Quarter 2021 Revenue Increases 709% to $15.3 Million Driven by N ew D iagnostic S ervices B usines s
ProPhase Labs (NASDAQ:PRPH) will issue its quarterly earnings data after the market closes on Thursday, May 13th. Analysts expect the company to announce earnings of $0.35 per share for the quarter. Parties interested in registering for the companys conference call can do so using this link. ProPhase Labs (NASDAQ:PRPH) last released its quarterly earnings results []
Gainers Arcadia Biosciences, Inc. (NASDAQ: RKDA ) rose 52% to $3.54 in pre-market trading after the company announced better-than-expected Q4 sales. ClearOne, Inc. (NASDAQ: CLRO ) rose 29.9% to $4.00 in pre-market trading. ClearOne shares fell over 6% on Tuesday after the company reported Q4 earnings results. X Financial (NYSE: XYF ) rose 20% to $4.02 in pre-market trading after gaining around 10% on Tuesday. Hywin Holdings Ltd. (NASDAQ: HYW ) shares rose 16.5% to $11.40 in pre-market trading. The company, last week, priced its IPO at $10 per ADS. CASI Pharmaceuticals, Inc. (NASDAQ: CASI ) rose 15.1% to $2.29 in pre-market trading. The company, on Tuesday, reported FY20 results.. ProPhase Labs, Inc. (NASDAQ: PRPH ) rose 14.5% to $7.18 in pre-market trading after the company disclosed that it has acquired mobile app company VaccTrack, which confirms a user has been vaccinated against COVID-19, for an undisclosed amount. Greenlane Holdings, Inc. (NASDAQ: GNLN ) rose 14.4% to $4.68 in pre-market trading after the company and KushCo announced a merger agreement.
Shares of ProPhase Labs Inc (NASDAQ: Full story available on Benzinga.com
ProPhase Labs Inc. shares closed 0.1% higher than its previous 52 week high, giving the company a market cap of $185M. The stock is currently up 74.2% year-to-date, up 773.8% over the past 12 months, and up 1740.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.1%, and the S&P 500 fell 0.2%. Trading Activity Trading volume this week was 0.9% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 5.4% higher than its 5-day moving average, 32.9% higher than its 20-day moving average, and 98.3% higher than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock priceperformance year-to-date beats the peer average by 440.9% The company's stock price performance over the past 12 months beats the peer average by 2239.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
ProPhase Labs Inc. shares closed 2.1% higher than its previous 52 week high, giving the company a market cap of $181M. The stock is currently up 70.6% year-to-date, up 760.1% over the past 12 months, and up 1583.3% over the past five years. This week, the Dow Jones Industrial Average rose 0.8%, and the S&P 500 rose 1.7%. Trading Activity Trading volume this week was 138.0% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock priceperformance year-to-date beats the peer average by 673.8% The company's stock price performance over the past 12 months beats the peer average by 2459.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) 10X Genomics Inc (NASDAQ: TXG ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) CareDx Inc (NASDAQ: CDNA ) Castle Biosciences Inc (NASDAQ: CSTL ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CTI BioPharma Corp (NASDAQ: CTIC ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) Inspire Medical Systems Inc (NYSE: INSP ) InVitae Corp (NYSE: NVTA ) Kura Oncology Inc (NASDAQ: KURA ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Novocure Ltd (NASDAQ: NVCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Prelude Therapeutics Inc (NASDAQ: PRLD ) ProPhase Labs Inc (NASDAQ: PRPH ) Qiagen NV (NYSE: QGEN ) Repligen Corporation (NASDAQ: RGEN ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Twist Bioscience Corp (NASDAQ: TWST ) Vericel Corp (NASDAQ: VCEL ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 6) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) (reacted to negative results for a mid-stage study of lenabasum in cystic fibrosis patients) Dyne Therapeutics Inc (NASDAQ: DYN ) Outset Medical Inc (NASDAQ: OM ) Teligent Inc (NASDAQ: TLGT ) Stocks In Focus Integra LifeSciences' Preliminary Q3 Revenues Exceed Estimate Medtech company Integra Lifesciences Holdings Corp (NASDAQ: IART ) preannounced third-quarter results, expecting revenues of $368 million to $370 million, down about 2.7%, but exceeding the company's guidance provided at …
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) 10X Genomics Inc (NASDAQ: TXG ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) argenx SE – ADR (NASDAQ: ARGX ) (presented positive new data from a Phase 3 trial evaluating efgartigimod in patients with generalized myasthenia gravis) Ascendis Pharma A/S (NASDAQ: ASND ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Blueprint Medicines Corp (NASDAQ: BPMC ) C4 Therapeutics, Inc. (NASDAQ: CCCC ) (went public Friday) Castle Biosciences Inc (NASDAQ: CSTL ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) CTI BioPharma Corp (NASDAQ: CTIC ) Cytokinetics, Inc. (NASDAQ: CYTK ) (reacted to presentations at the Heart Failure Society of America virtual meeting) Eidos Therapeutics Inc (NASDAQ: EIDX ) - announced a deal to be bought by BridgeBio Pharma Inc (NASDAQ: BBIO ) EXACT Sciences Corporation (NASDAQ: EXAS ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Kura Oncology Inc (NASDAQ: KURA ) LifeSci Acquisition Corp (NASDAQ: LSAC ) Myokardia Inc (NASDAQ: MYOK ) - announced a deal to be bought by Bristol-Myers Squibb Co (NYSE: BMY ) for $13.
DOYLESTOWN, Pennsylvania, March 25, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com) today announced its net sales were…